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ABSTRACT 
 
Aims 
To assess contemporary pre-test probability estimates for obstructive coronary artery disease in 
patients with stable chest pain. 
Methods and results 
In a substudy of a multicentre randomised controlled trial, we compared 2019 European Society 
of Cardiology (ESC)-endorsed pre-test probabilities with observed prevalence of obstructive 
coronary artery disease on computed tomography coronary angiography (CTCA). We assessed 
associations between pre-test probability, 5-year coronary heart disease death or non-fatal 
myocardial infarction and study intervention (standard care versus CTCA).  
The study population consisted of 3755 patients (30-75 years, 46% women) with a median pre-
test probability of 11% of whom 1622 (43%) had a pre-test probability >15%. In those who 
underwent CTCA (n=1613), the prevalence of obstructive disease was 22%. When divided into 
deciles of pre-test probability, the observed disease prevalence was similar but higher than the 
corresponding median pre-test probability (median difference 2.3 [1.3–5.6]%). There were more 
clinical events in patients with a pre-test probability >15% compared to those at 5-15% and 
<5% (4.1%, 1.5% and 1.4% respectively, p<0.001). Across the total cohort, fewer clinical events 
occurred in patients who underwent CTCA, with the greatest difference in those with a pre-test 
probability >15% (2.8% vs 5.3%, log rank p=0.01), although this interaction was not statistically 
significant on multivariable modelling.  
Conclusion 
The updated 2019 ESC guideline pre-test probability recommendations tended to slightly 
underestimate disease prevalence in our cohort. Pre-test probability is a powerful predictor of 
future coronary events and helps select those who may derive the greatest absolute benefit from 
CTCA. 
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INTRODUCTION 
 
Chest pain is one of the commonest symptoms in patients presenting to the cardiology clinic. 
Determining whether obstructive coronary artery disease is the underlying cause requires a 
combination of clinical evaluation and, where appropriate, non-invasive or invasive 
investigations. However, additional testing should only be applied to an appropriately selected 
population, taking into account disease prevalence and the diagnostic performance of the test. 
Inappropriate testing may lead to under or over diagnosis of coronary artery disease, with 
potential misallocation of downstream invasive angiography and therapies. This is pertinent in 
the current era, where a broad range of functional and anatomical investigations across a 
spectrum of cost and availability can be performed. Furthermore, pre-test probabilities derived 
from historic cohorts have consistently overestimated contemporary disease prevalence (1-4), 
undoubtedly leading to over-testing. 
 
The latest 2019 European Society of Cardiology (ESC) guidelines for chronic coronary 
syndromes (5) have re-evaluated the assessment of patients with stable chest pain presenting to 
the outpatient cardiology clinic. The guideline has updated estimation of pre-test probability for 
obstructive coronary artery disease based on chest pain type, age and gender using more 
contemporaneous data from the Coronary CT Angiography Evaluation For Clinical Outcomes: 
An International Multicenter (CONFIRM) Registry, the CT group of the Prospective 
Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) randomised controlled trial 
and a retrospective single-centre angiographic cohort (1, 3, 4, 6). The thresholds that warrant 
further downstream testing have also been revised such that patients with a pre-test probability 
<5% are not recommended to undergo further testing, while testing is deemed appropriate in 
those with a pre-test probability >15%. Patients with an intermediate pre-test probability of 5-
15% are recognised to have a good prognosis and testing may safely be deferred, although 
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discretionary investigation can have a role. If testing is to be performed, the choice of test is 
determined by several factors, but in general, the guideline authors favour functional testing 
where the likelihood of obstructive disease is higher, and CT coronary angiography (CTCA) 
where the likelihood is lower.   
 
In this study, we assessed the latest ESC-endorsed pre-test probability estimates for obstructive 
coronary artery disease in the Scottish COmputed Tomgraphy of the HEART (SCOT-HEART, 
NCT01149590) trial population. We aimed to (i) validate the prediction of obstructive coronary 
artery disease by pre-test probability in our external cohort, (ii) assess the prognostic value of 
pre-test probability, and (iii) examine whether the use of CTCA was associated with a difference 
in clinical outcomes across pre-test probability strata. 
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METHODS 
 
Study population 
This is a post-hoc analysis of the open-label, randomised Scottish Computed 
Tomography of the Heart (SCOT-HEART) trial. The trial design, primary analysis and 5-year 
outcomes have been reported previously (7-9). In brief, SCOT-HEART enrolled patients 18-75 
years of age who were assessed in cardiology clinics with stable chest pain and randomised them 
to either routine care or routine care plus CTCA. Between November 2010 and September 2014, 
4146 patients were recruited from 12 centres across Scotland. Major exclusion criteria included 
severe chronic kidney disease (serum creatinine >200 mol/L or estimated glomerular filtration 
rate <30 mL/min/1.73 m2) and acute coronary syndrome within 3 months. Ethical approval was 
provided by the South East Scotland Research Ethics Committee 02, Edinburgh, UK 
(10/S1102/43). To maintain consistency with the revised ESC guidelines, for this analysis we 
excluded patients with previously documented coronary heart disease and those <30 years of 
ages.   
 
Risk group assignment and endpoints 
Patients were assigned a pre-test probability using chest pain type (typical, atypical or non-
anginal according to major society guidelines) (5, 10) age groups and gender according to ESC 
guidelines (5). Typical angina is defined as the following three criteria: (i) constricting discomfort 
in the chest, neck, jaw, shoulder or arm that is (ii) precipitated by exertion and (iii) relieved by 
rest or nitrates within 5 min. Atypical angina meets two of these criteria, while non-anginal 
symptoms meet one or none. Patients were then categorised as low (<5%), intermediate (5-15%) 
or high pre-test probability (>15%). 
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The presence of obstructive coronary artery disease was defined as coronary artery area stenosis 
>70% in a major epicardial vessel or >50% in the left main stem on CTCA as previously 
reported (7). The clinical endpoint was coronary heart disease death or non-fatal myocardial 
infarction at 5 years (8). 
 
Statistical analysis 
Continuous variables are reported as median (interquartile range, [IQR]) and were compared 
with the Kruskal-Wallis test. Categorical variables were compared with the Chi-squared test.  
To validate the ESC pre-test probability estimates, patients were assigned a pre-test probability 
according to age, gender and chest pain type and were compared with the observed prevalence in 
those patients who underwent CTCA. The study cohort was then divided into deciles according 
to pre-test probability. For each decile, median [IQR] pre-test probability and observed 
prevalence were determined.  
 
For the clinical endpoint of non-fatal myocardial infarction or coronary heart disease death, 
cumulative event rates were examined using Kaplan-Meier curves and the log-rank test. 
Univariable and multivariable Cox proportional hazards models were constructed to determine 
clinical factors associated with the combined endpoint and to test the effect of CTCA with pre-
test probability as an interaction. Variables included ESC pre-test probability category, study 
allocation and the remaining clinical variables used for minimisation in the primary trial design 
(body-mass index, diabetes mellitus and atrial fibrillation). Two-sided p-values <0.05 were 
considered statistically significant. Analysis was performed using R version 3.5.0 (R Foundation 
for Statistical Computing, Vienna, Austria). 
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RESULTS 
 
Of the 4146 patients enrolled in SCOT-HEART, 376 were excluded due to documented 
coronary heart disease (n=372) or missing data for this field (n=4) and 15 patients were <30 
years of age, leaving a study population of 3755 (Table 1; Supplementary Figure 1).  
 
Distribution of pre-test probabilities 
Less than half the cohort had a pre-test probability >15% (n=1622, 43%). These patients were 
older and predominantly male (n=1300, 80.1%) with a preponderance of typical symptoms. The 
intermediate group (pre-test probability 5-15%) were predominantly female (n=914, 70.2%) 
(Figure 1a). Those not recommended for further investigation (pre-test probability <5%) had a 
more balanced gender distribution (n=352, 42.4% males). There was a higher prevalence of 
cardiovascular risk factors and concomitant cardiovascular disease in the >15% group, including 
hypertension, hyperlipidaemia, diabetes mellitus, cerebrovascular disease and peripheral vascular 
disease. Baseline preventative therapies increased with pre-test probability (Table 1, p<0.001 for 
all).  
 
Pre-test probability and observed prevalence 
Amongst the 1613 patients who underwent CTCA, there was an increase in non-obstructive and 
obstructive disease across pre-test probability categories as well as an increase in coronary artery 
calcium score (Figure 1b, Table 2). There was a similar distribution of pre-test probabilities and 
observed prevalence of obstructive coronary artery disease in the CT cohort across patient 
categories (Table 3), with most groups having the same recommended strategy for further 
testing. The highest observed prevalence was in males >70 years with typical angina (61%) – the 
highest pre-test probability group (52%). Overall, men had a higher observed prevalence than 
women within each age and symptom strata, apart from non-anginal chest pain in those <30-39 
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years (where absolute numbers were low). All groups of women <70 years with atypical or non-
anginal chest pain had both a pre-test probability and an observed prevalence of <15%. Deciles 
of pre-test probability and the observed prevalence within each decile are presented in Figure 2 
and Supplementary Figure 2. Notably, 5 of the deciles had a median pre-test probability 
<15%, each with a corresponding median observed prevalence <15%. The observed prevalence 
of disease in each decile was similar but consistently higher than the corresponding median pre-
test probability (median difference 2.3 [1.3–5.6]%) 
 
For all ESC categories of patients with a pre-test probability >15%, there was a corresponding 
observed prevalence of >15%.  Conversely, three groups of patients (n=130, 8%) had a pre-test 
probability between 5-15% but an observed prevalence >15%. Two-thirds of these patients were 
female (n=89). Of the female patients, 66 had typical angina and 23 had non-anginal symptoms, 
with a median age of 57 (53-70 years). In contrast, the 41 males were from the group aged 40-49 
(median 45 [43-47]) years with atypical angina. 
 
Pre-test probability, outcomes and study allocation 
The combined endpoint of death from coronary heart disease or non-fatal myocardial infarction 
was met in 66 of 1622 (4.1%) patients with a high pre-test probability, 19 of 1302 with 
intermediate pre-test probability (1.5%) and 12 of 831 (1.4%) with low pre-test probability 
(Figure 3, p<0.001 between groups).  
 
Events were further stratified within each group according to study arm allocation (CT or 
standard care; Figure 4, Table 4). There was more change in preventative medical therapies 
with the use of CTCA (Supplementary Table 1). There were numerically fewer events in those 
patients who were randomised to CTCA, which was most evident in the high pre-test probability 
group (43 of 807 (5.3%) standard care versus 23 of 815 (2.8%) CTCA, p=0.01). Within this group, 
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there appeared to be fewer events in the CTCA arm regardless of whether patients were above 
or below the median pre-test probability (26%) (Supplementary Figure 3, Supplementary 
Table 2). On Cox regression analysis, a high pre-test probability was a strong predictor of the 
combined endpoint on both univariable and multivariable analysis (hazard ratio 2.92, 95% 
confidence interval 1.37-6.20, p=0.006). The use of CTCA was associated with a lower risk of 
the combined endpoint on univariable but not multivariable analysis, while there was no 
significant interaction between pre-test probability and the use of CTCA with respect to clinical 
outcomes (pinteraction 0.75 and 0.95 for intermediate and high pre-test probability respectively; 
Supplementary Table 3). 
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DISCUSSION 
 
In this study, we demonstrate that the 2019 ESC estimates of pre-test probability for obstructive 
coronary artery disease in suspected stable angina are broadly similar to the observed prevalence 
in the SCOT-HEART trial cohort, although it now tends to underestimate prevalence. In this 
representative and general population of patients referred with stable chest pain to a cardiology 
clinic, less than half of patients would need further testing according to the current ESC 
guidelines. Furthermore, we have confirmed the strong prognostic value of pre-test probability 
and shown that CTCA may be most beneficial in those with a pre-test probability >15%.  
 
Major society guidelines are an integral part of modern clinical medicine. As expert consensus 
documents, they provide a framework for best evidence-based practice within the limits of 
available data. It is, however, important for clinicians to tailor their approach on an individual 
basis, taking into account factors such as patient preferences, local resources and differences 
between the patient at hand and derivation populations used to formulate guidelines. It has been 
established across several cohort studies that the previous ESC Diamond and Forrester pre-test 
probabilities overestimated the prevalence of disease, with a previous collaboration between 
SCOT-HEART and PROMISE investigators demonstrating more identification of low-risk 
patients with the symptom-based National Institute of Health and Care Excellence guidelines 
(11). Indeed, although not the focus of this analysis, the Diamond and Forrester estimates 
exceeded the observed disease prevalence in nearly all groups in our cohort (Table 3). This led to 
changes in the most recent iteration of the ESC guidelines (5, 12) which pooled three separate 
cohorts for this update. It is important to understand the patient populations, definitions and 
potential biases used in these derivation cohorts, two of which were registries of consecutive 
patients and the third of which was a randomised controlled trial. Cheng et al (1) comprised 
14048 consecutive patients from the CONFIRM registry from Canada, Italy, South Korea, 
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Switzerland, Germany and the United States. The presence of coronary artery disease was 
defined as a luminal diameter stenosis of ≥50% in any segment ≥1.5 mm in diameter. Although 
these patients had suspected coronary artery disease and underwent CTCA, only 8106 reported 
non-anginal chest pain, atypical angina or typical anginal symptoms, and only this subgroup was 
included in the pooled analysis. Foldyna et al (3) consisted of 4415 patients from the CT cohort 
of the randomized PROMISE trial, which tested functional testing against CTCA in 
symptomatic outpatients in whom physicians felt diagnostic testing for coronary artery disease 
was indicated (13). One-quarter of patients did not have chest pain as the presenting symptom, 
and of those that did, only 12% had typical angina. This study defined obstructive coronary 
disease as a diameter stenosis of ≥50% in any vessel with a calibre >2 mm. All recruiting centres 
in PROMISE were in North America. Reeh et al (4) retrospectively assessed 3903 patients who 
underwent invasive angiography at a single Danish centre for investigation of suspected angina. 
Most patients had already undergone at least one other test prior to angiography. In this study, 
obstructive disease was defined as a lesion requiring revascularization, diameter stenosis >70% 
or a fractional flow reserve <0.80. In contrast to these populations, the SCOT-HEART trial was 
designed as a pragmatic randomised trial and recruited a broader and less selected population of 
patients with suspected stable angina. Despite some differences in the pooled derivation 
population and the method used to diagnose obstructive coronary artery disease, we have shown 
a broadly similar distribution of ESC pre-test probabilities and observed disease prevalence in 
SCOT-HEART. Indeed, the highest pre-test probability – in males >70 years with typical angina 
– was 52% in the guideline cohort, correlating with an observed prevalence of 62% in SCOT-
HEART. Importantly, all patients with a pre-test probability >15% belonged to groups that had 
a corresponding observed prevalence of >15%, while 8% of the cohort had a pre-test probability 
of 5-15% but belonged to groups that had a prevalence of >15%. This provides further evidence 
demonstrating the overestimation of previous pre-test probabilities, while highlighting 
differences between the ESC derivation populations and SCOT-HEART, where we found that 
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the pre-test probability underestimated prevalence in some patients. We believe that this likely to 
reflect differences in the populations studied, with SCOT-HEART including a broader risk 
spectrum of patients as we have reported previously (14). 
 
In our current analysis, it would appear that less than half of patients referred with stable chest 
pain to the cardiology clinic will need further testing. Importantly, a large proportion of women 
will avoid investigations. Only women >60 years with typical angina or women >70 years with 
atypical angina have a pre-test probability >15%. In our cohort, an observed prevalence >15% 
was found in women >50 years with typical angina and women >70 years with any chest pain. 
These findings are important in light of recent gender disparities seen in SCOT-HEART, where 
women had proportionally more normal coronary arteries and less obstructive disease than men 
(15). Adoption of the latest guidelines may therefore result in less unnecessary investigations in 
women. Importantly, recent data have challenged the historic notion that women with 
myocardial infarction present more atypically than men (16). Although in SCOT-HEART there 
were relatively more women recruited with atypical chest pain, the low observed prevalence of 
disease in these groups confirms the importance of assessing symptoms on their own merit, 
independent of gender.  
 
The concept of what constitutes low, intermediate and high pre-test probability remains open for 
debate and is, to a degree, subjective. The previous 2013 ESC guidelines suggested that a pre-test 
probability of 15-85% constituted intermediate likelihood and further testing was warranted in 
the majority of patients (12). The 2019 ESC guidelines suggest that deferral of routine testing is 
safe in those with a pre-test probability of <15%, although discretionary testing if pre-test 
probability is 5-15% can be considered. However, pre-test probabilities for each patient group 
have been reduced, in recognition of prior overestimates of disease. Consequently, a much 
greater proportion of patients may be safely managed without further investigation, thus 
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avoiding unnecessary tests in a group of patients with a low risk of adverse outcome (annual risk 
of cardiovascular death or myocardial infarction <1%) (5). Our findings support this more 
conservative approach, with similarly low event rates in the <5% and 5-15% pre-test probability 
groups. Thus, reserving further investigation for those with a pre-test probability >15% may be 
an appropriate strategy. There will, of course, be scenarios where testing may be warranted in the 
5-15% or even <5% groups, with many possible factors to consider. The negative predictive 
value of CTCA means that for some patients, the reassurance of a normal CTCA has major 
value and can reduce unnecessary anxiety and treatments (17). 
 
When proceeding to further investigation, what imaging modality should be used? After 
accounting for local factors such as availability and expertise, the ESC guidelines recommend 
functional testing when there is a higher likelihood of disease (previously >50% pre-test 
probability) and CTCA when there is a lower likelihood (previously 15-50%) (5, 12). A recent 
meta-analysis based on Diamond and Forrester pre-test probabilities demonstrated CTCA to be 
most accurate in patients with a pre-test probability between 7% and 67% (18). A specific 
threshold is not stated in the latest guidelines but applying a 50% threshold to the current pre-
test probabilities would infer that nearly all patients should have CTCA where possible. The 
recommendation for functional testing in patients with >50% pre-test probability is largely based 
on the recognised potential for discordance between anatomical stenosis severity and the 
haemodynamic effects of a lesion (19). Functional stress testing may provide valuable 
information about ischaemia in myocardial segments, as well as potential information about the 
patient’s functional capacity, which in itself is related to prognosis (20). However, functional 
testing does not provide anatomical information at a vessel or lesion level, nor does it provide 
adjunctive information regarding overall plaque burden. In this study, we found that within the 
>15% pre-test probability group, there appeared to be a similar proportionate reduction in the 
rate of fatal or non-fatal myocardial infarction in those above and below the median pre-test 
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probability in those who underwent CTCA. This is an exploratory finding only, and we did not 
demonstrate a significant interaction between pre-test probability and the use of CTCA on 
multivariable analysis, but it highlights the need to balance the strengths and weaknesses of 
various available imaging modalities, as well as the intended purpose of the test: to help diagnose 
and manage symptoms of suspected angina due to obstructive coronary artery or prevent future 
myocardial infarction. Regardless of the imaging test chosen, studies have demonstrated a 
reduction in the rate of non-obstructive coronary artery disease on invasive angiography when an 
imaging test is performed beforehand (13, 21, 22), although CTCA is associated with the lowest 
rates of normal invasive angiography. 
 
Perhaps not surprisingly, pre-test probabilities also track with future risk of events given that the 
presence and extent of obstructive coronary artery disease is a powerful predictor of future risk 
of adverse coronary events. Non-obstructive as well as obstructive disease increases across pre-
test probability categories, and it is widely recognised that non-obstructive plaque and overall 
atherosclerotic burden strongly correlate with outcomes (23-25). 
  
This study is a post-hoc subgroup analysis and the results are hypothesis-generating only. 
Although our findings are largely consistent with contemporary pre-test probability estimates, 
the observed prevalence within each category of age band, sex and chest pain type are based on 
relatively small numbers. In particular, the cohort is underpowered to conclusively demonstrate 
the benefit of CTCA within subgroups of pre-test probability (particularly the lower two strata) 
with regards to clinical outcomes. Further data to confirm the benefits of discretionary testing in 
patients with a pre-test probability 5-15% would be of substantial interest. We did not include 
dyspnoea as a symptom in SCOT-HEART and were thus unable to validate the ESC pre-test 
probabilities for this group. However, our main findings are congruent with the large existing 
body of literature that has demonstrated the overdiagnosis of coronary artery disease when 
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utilising previous pre-test probability models. Our findings are also in keeping with the data 
upon which the guidelines are based, promoting a more conservative approach to the use of 
downstream investigations in patients with suspected stable angina, and demonstrating that the 
greatest benefits of CTCA appears to be in those with a pre-test probability >15% (26).  
 
CONCLUSION 
The pre-test probabilities for obstructive coronary artery disease recommended by the 2019 ESC 
chronic coronary syndrome guidelines are broadly consistent with the SCOT-HEART trial 
cohort, although prevalence is underestimated in some groups. Patients with a high pre-test 
probability had a worse prognosis and this group had the greatest numerical reduction in events 
with allocation to CTCA. These findings provide strong support for the recommended strategy 
of offering non-invasive imaging to patients with a pre-test probability of >15%.  
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FIGURE LEGENDS 
 
FIGURE 1 
1a) – Distribution of ESC pre-test probabilities in the study cohort, stratified by gender.  
1b) – Prevalence of disease on CTCA in each ESC group in patients who underwent CTCA.  
Abbreviations: ESC, European Society of Cardiology; CTCA, computed tomography coronary 
angiography.  
 
FIGURE 2 
ESC pre-test probability vs observed disease prevalence. Each point represents the median ESC 
pre-test probability per decile of the study population, plotted against the observed prevalence 
within each decile.  The diagonal reference line represents perfect agreement. The shaded blue 
rectangles denote pre-test probabilities and prevalence of <15% - patients in whom testing may 
be safely deferred.  
Abbreviations: ESC, European Society of Cardiology. 
 
FIGURE 3 
Cumulative incidence of coronary heart disease death or non-fatal myocardial infarction stratified 
by ESC pre-test probability categories.  
Abbreviations: ESC, European Society of Cardiology; PTP, pre-test probability. 
 
FIGURE 4 
Cumulative incidence of coronary heart disease death or non-fatal myocardial infarction for each 
ESC pre-test probability category, stratified by study allocation.  
Abbreviations: ESC, European Society of Cardiology; PTP, pre-test probability. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjqcco/advance-article-abstract/doi/10.1093/ehjqcco/qcaa006/5715582 by Edinburgh U
niversity user on 27 January 2020
 23 
SUPPLEMENTARY FIGURE 1 
CONSORT diagram.  
Abbreviations: CTCA, computed tomography coronary angiography. 
 
SUPPLEMENTARY FIGURE 2 
ESC pre-test probability versus observed disease prevalence in each chest pain group. Each data 
point represents one ESC group based on age, sex and gender.  
Abbreviations: ESC, European Society of Cardiology. 
 
SUPPLEMENTARY FIGURE 3 
Cumulative incidence of coronary heart disease death or non-fatal myocardial infarction in the 
high pre-test probability group, divided into those above and below the median (26%) and 
stratified by study allocation.  
Abbreviations: ESC, European Society of Cardiology; PTP, pre-test probability. 
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 Table 1 Baseline characteristics stratified by pre-test probability 
 
 Overall <5% 5-15% >15% p 
n 3755 831 1302 1622  
Female 1715 (45.7) 479 (57.6) 914 (70.2) 322 (19.9) <0.001 
Age 57.0 [50.0, 64.0] 47.0 [42.0, 51.5] 56.0 [51.0, 61.0] 63.0 [58.0, 68.0] <0.001 
Chest pain type     <0.001 
     Non-anginal 1606 (42.8) 789 (94.9) 566 (43.5) 251 (15.5)  
     Atypical angina 889 (23.7) 25 (3.0) 492 (37.8) 372 (22.9)  
     Typical angina 1260 (33.6) 17 (2.0) 244 (18.7) 999 (61.6)  
Hypertension 1211 (32.5) 159 (19.3) 402 (31.2) 650 (40.3) <0.001 
Hyperlipidaemia 2078 (55.3) 299 (36.0) 662 (50.8) 1117 (68.9) <0.001 
Diabetes 370 (9.9) 58 (7.0) 123 (9.4) 189 (11.7) 0.001 
Family history CAD 1549 (41.7) 376 (45.7) 606 (47.1) 567 (35.2) <0.001 
Smoking history     <0.001 
     Non-smoker 770 (20.5) 253 (30.4) 276 (21.2) 241 (14.9)  
     Ex-smoker 1177 (31.4) 193 (23.2) 369 (28.3) 615 (38.0)  
     Current smoker 1806 (48.1) 385 (46.3) 657 (50.5) 764 (47.2)  
Cerebrovascular disease 123 (3.3) 13 (1.6) 35 (2.7) 75 (4.6) <0.001 
Peripheral vascular 
disease 
42 (1.1) 6 (0.7) 7 (0.5) 29 (1.8) 0.003 
Systolic blood pressure 
(mmHg) 
140.0 [125.0, 
152.0] 
130.0 [120.0, 
145.0] 
140.0 [125.0, 
152.0] 
140.0 [130.0, 
157.0] 
<0.001 
Diastolic blood 
pressure (mmHg) 
80.0 [76.0, 90.0] 80.0 [75.0, 89.0] 81.0 [76.0, 90.0] 80.0 [77.0, 90.0] 0.044 
Body mass index 
(kg/m2) 
28.8 [25.6, 32.8] 29.1 [25.2, 33.1] 29.0 [25.6, 33.8] 28.5 [25.8, 31.9] 0.029 
Antiplatelet 1662 (44.3) 121 (14.6) 493 (37.9) 1048 (64.6) <0.001 
Statin 1459 (38.9) 103 (12.4) 405 (31.1) 951 (58.6) <0.001 
ACE inhibitor 497 (13.2) 66 (7.9) 143 (11.0) 288 (17.8) <0.001 
Beta-blocker 786 (20.9) 57 (6.9) 215 (16.5) 514 (31.7) <0.001 
 
Abbreviations: CAD, coronary artery disease 
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Table 2 CTCA findings stratified by pre-test probability 
 
 <5% 5-15% >15% p 
n 311 569 733  
CTCA    <0.001 
   Normal 216 (69.5) 262 (46.0) 152 (20.7)  
   Mild (<50%) 54 (17.4) 141 (24.8) 158 (21.6)  
   Moderate (50-70%) 26 (8.4) 104 (18.3) 141 (19.2)  
   Obstructive 15 (4.8) 62 (10.9) 282 (38.5)  
Calcium score (AU) 0.0 [0.0, 3.0] 1.0 [0.0, 47.0] 111.0 [6.0, 444.0] <0.001 
 
Abbreviations: CTCA, computed tomography coronary angiography; AU, Agatston units 
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Table 3 Pre-test probabilities and observed prevalence of obstructive coronary artery disease  in 
SCOT-HEART 
 
ESC 2013 
Typical Atypical Non-anginal 
M F M F M F 
30-39 59% 28% 29% 10% 18% 5% 
40-49 69% 37% 38% 14% 25% 8% 
50-59 77% 47% 49% 20% 34% 12% 
60-69 84% 58% 59% 28% 44% 17% 
70+ 89% 68% 69% 37% 54% 24% 
       
ESC 2019 
Typical Atypical Non-anginal 
M F M F M F 
30-39 3% 5% 4% 3% 1% 1% 
40-49 22% 10% 10% 6% 3% 2% 
50-59 32% 13% 17% 6% 11% 3% 
60-69 44% 16% 26% 11% 22% 6% 
70+ 52% 27% 34% 19% 24% 10% 
       
SCOT-HEART 
Typical Atypical Non-anginal 
M F M F M F 
30-39 
0% 0% 0% 0% 0% 13% 
0/2 0/3 0/5 0/5 0/18 1/8 
40-49 
30% 9% 17% 0% 6% 4% 
9/30 3/33 7/41 0/44 6/107 2/53 
50-59 
57% 18% 21% 12% 12% 5% 
65/114 12/66 16/75 8/67 15/125 6/110 
60-69 
53% 27% 37% 6% 17% 9% 
77/146 24/89 19/52 4/67 16/92 9/103 
70+ 
61% 30% 54% 21% 33% 17% 
28/46 11/37 7/13 5/24 5/15 4/23 
 
Grey shading denotes a pre-test probability of 5-15% (intermediate likelihood) in whom 
discretionary testing is reasonable. Green shading denotes a pre-test probability >15%, in whom 
further investigation is recommended.  
 
Abbreviations: ESC, European Society of Cardiology; SCOT-HEART, Scottish COmputed 
Tomography of the HEART; M, male; F, female. 
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Table 4 Clinical outcomes 
 
Pre-test probability Standard care CTCA p 
<5% 434 397  
     NFMI/CHD death 8 (1.8) 4 (1.0) 0.31 
     NFMI 7 (1.6) 3 (0.8)  
     CHD death 1 (0.2) 1 (0.3)  
    
5-15% 638 664  
     NFMI/CHD death 11 (1.7) 8 (1.2) 0.44 
     NFMI 11 (1.7) 8 (1.2)  
     CHD death 0 0  
    
>15% 807 815  
     NFMI/CHD death 43 (5.3) 23 (2.8) 0.01 
     NFMI 39 (4.8) 21 (2.6)  
     CHD death 5 (0.6) 2 (0.2)  
 
Abbreviations: CTCA, computed tomography coronary angiography; NFMI, non-
fatal myocardial infarction; CHD, coronary heart disease 
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Figure 1b
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